DSP-5336

A Phase 1, Open-label Study of the Absorption, Metabolism, and Excretion of DSP-5336 Following a Single Oral Dose in Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndrome, Multiple Myeloma, or Myeloproliferative Neoplasms

What's the purpose of the trial?

The purpose of this study is to evaluate the absorption, metabolism, and excretion of DSP-5336 following a single oral administration of the study drug in patients with hematologic malignancies whose disease has progressed after available standard therapies.
Trial status

Accepting patients

Phase
Phase 1
Enrollment
8
Last Updated

Participating Centers

There are 2 centers participating in this trial. Enter a location below to find the closest center.

Experimental Treatments

Learn more about the experimental treatments being evaluated in this clinical trial.

  • Enzomenib is a type of drug called a menin inhibitor. Enzomenib may help to slow the growth of certain types of cancer cells.

Arms / Cohorts

Explore eligibility, treatments and learn more about potential cohorts.

Accepting patients

Optional Continued Access

Accepting patients

DSP-5336 tablets and [14C]-DSP-5336 solution

Real People. Real Support.

Need help connecting with this clinical trial? We're here to help!

Print Report

Print a patient-friendly report to share with your patient.

(888) 850-0650

We can help answer any questions and connect you (or your patient) with the study team.

Schedule Call

Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.